PENNEX CLASS III RECALL OF 50 MIL. OTC ANALGESIC, ALLERGY
Executive Summary
PENNEX CLASS III RECALL OF 50 MIL. OTC ANALGESIC, ALLERGY and vitamin tabs is expected to be completed by Aug. 1. The Verona, Pennsylvania company told its customers in a June 26 letter that a credit would be issued for all of the recalled merchandise returned or destroyed. Pennex manufactured the aspirin mainly for private label distribution by a broad range of customers including chain drug stores, supermarkets, independent pharmacy coops, and distributors. The aspirin products were recalled due to trace contamination with aromatic hydrocarbons discovered by the firm as a result of a handful of complaints regarding malodor in bottles. The company explained to its customers that the contamination was introduced by the solvent used in the coating procedure. The solvent, Pennex said, was originally made by Dow Chemical and shipped in bulk to Pittsburgh where it was put into a drum by a local company for Pennex use. Trace levels of the contaminant were apparently introduced into the solvent during shipping, Pennex said, and were not detected by the firm's normal testing procedures which included an assay of the solvent by the USP method. The company explained that "two months later, after many batches of tablets were made using this lot of solvent" the odor was discovered on the finished products, and the decision was made to issue the recall in spite of the fact that no health hazard was involved. Pennex told its customers that in addition to its normal testing procedures, it was instituting "odor tests" on all solvents and all finished tablets.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth